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Objectives Baloxavir acid (BXA) is an endonuclease inhibitor approved for use against 
influenza. We evaluated whether this compound also targets the endonuclease domain of 
orthobunyaviruses and therefore could potentially be used against orthobunyavirus infections. 
Methods We performed a thermal shift assay and a FRET-based nuclease-monitoring assay 
using the LACV endonuclease and BXA to prove their interaction and identify an inhibitory 
effect. Their interaction was further studied in a docking simulation using Glide SP. We show 
that BXA inhibits the viral replication of BUNV-mCherry in vitro using high content imaging 
and virus yield assay. Lastly, we investigated the use of BXA in combination with ribavirin in 
vitro by implementing the Zero Interaction Potency (ZIP) response surface model. 
Results We show that BXA augments LACV enzyme’s melting temperature with Δ Tm 9.5 ± 
0.4 °C  and inhibited substrate cleavage with IC50 0.39 ± 0.03 μM. Moreover, our docking 
simulation suggests BXA is able to establish an efficient binding with the LACV endonuclease. 
In the cell based assay we observed BXA and ribavirin inhibited BUNV-mCherry with an 
EC50 of 0.7 ± 0.2 µM and 26.6 ± 8.9M, respectively. When used in combination we found a 
maximum synergistic effect of 8.64. 
Conclusions The influenza endonuclease inhibitor BXA is able to bind and interfere with the 
endonuclease domain of orthobunyaviruses and yields a more potent antiviral effect than 
ribavirin against BUNV-mCherry. The combination of both compounds results in a more 




Orthobunyaviruses (Order: Bunyavirales, Family: Peribunyaviridae) are a large genus of 
segmented negative single-stranded RNA viruses ((-)ssRNA), of which several members can 
cause mild to severe disease in humans.1 Bunyamwera virus (BUNV) is the type species and 
model system for the genus. Additionally, it is considered an emerging pathogen and is known 
to form reassortments that can be highly pathogenic (i.e. Ngari virus).2 La Crosse 
virus (LACV) is the leading cause of pediatric arboviral encephalitis in the USA.3 No specific 
treatment is available for orthobunyaviruses, but the guanosine analog ribavirin has been used 
in a clinical trial against LACV.4 However, this was discontinued due to adverse events caused 
by the occupied doses. 
As all segmented (-)ssRNA viruses, orthobunyaviruses rely on their own transcriptional 
machinery in the form of an RNA-dependent RNA polymerase (RdRp). The endonuclease 
domain of this protein cleaves 5’-RNA caps from host cells mRNA, a process dubbed ‘cap-
snatching’.5 Cap-snatching is a conserved feature amonall (-)ssRNA viruses and therefore a 
promising antiviral target. The influenza endonuclease domain is a known antiviral target for 
which multiple antiviral molecules have been identified. Baloxavir marboxil (BXM), the 
prodrug of baloxavir acid (BXA), is a first-in-class endonuclease-targeting influenza 
antiviral approved for clinical use by the FDA in 2019.6,7   
In this work we show the effects BXA has on the stability and enzymatic activity of 
the endonuclease domain of 
LACV and investigate the interaction between BXA and the endonuclease through a docking 
simulation. Furthermore, we show that BXA inhibits the viral replication of BUNV in 
vitro and that its use in combination with ribavirin resulted in a synergistic antiviral effect. 
Methods 
Thermal shift assay 
The stability of LACV_L1-184_WT, produced as previously reported, was measured using a 
thermal shift assay (TSA) using a protein concentration of 10 μM in 100 mM Tris pH 7.0, 250 
mM NaCl, 5% glycerol complemented or not with 25 μM of BXA in the presence of 10 mM 
EDTA or 10 mM MnCl2 as described.8,9 
FRET-based nuclease-monitoring assay 
Serial dilutions of BXA were pre-incubated for 15 min with 0.25 μM of LACV_L1-184_WT in a 
mixture consisting of 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol, 0.05 U/µl RNasin 
(Promega) and 10 mM MnCl2 or EDTA. The reactions were initiated by the addition of 1 µM 
of a 12mer poly(A) ssRNA substrate labeled at the 5´ end with fluorophore 6-FAM and the 3´ 
end with quencher BHQ-1 (Biomers). The fluorescence signal was measured every 10 s for 20 
min in a 96-well plate format at wavelengths 490 nm and 515 nm for excitation and emission, 
respectively. The initial velocity of the reactions (V0) was determined as the slope of the linear 
phase of the progress curves, and the percentages of the enzymatic activity were plotted against 
the concentrations of the compounds on a semilogarithmic graph. The half-
maximum inhibitory concentration (IC50) was calculated by nonlinear regression analysis 
performed using GraphPad Prism version 7.00 (GraphPad Software, La Jolla California USA, 
www.graphpad.com). 
Molecular Modelling 
All molecular docking studies were performed on a Viglen Genie Intel®CoreTM i7-3770 vPro 
CPU@ 3.40 GHz x 8 running Ubuntu 18.04. Molecular Operating Environment (MOE) 
2019.109 and Maestro (Schrödinger Release 2019-3) was used as molecular modelling 
software.10,11 
The available X-ray structure of the LACV N-terminal endonuclease domain (PDB: 
2XI7) was pre-processed using the Schrödinger Protein Preparation Wizard by assigning bond 
orders, adding hydrogens and performing a restrained energy minimization of the added 
hydrogens using the OPLS_2005 force field.5 BXA was built with MOE and then prepared 
using the Maestro LigPrep tool by energy minimizing the structures (OPLS_2005 force filed), 
generating possible ionization states at pH 7 ± 2, generating tautomers and low-energy ring 
conformers. A 12 Å docking grid (inner-box 10 Å and outer-box 20 Å) was prepared using as 
centroid the Mn atoms. Molecular docking studies were performed using Glide SP precision 
keeping the default parameters and setting 5 as number of output poses per input ligand to 
include in the solution. The output poses were saved as sdf file. The docking results were 
visually inspected for their ability to bind the active site, using MOE. 
Cell based antiviral activity assay 
The antiviral activity of BXA and ribavirin against BUNV-mCherry was evaluated in A549 
cells (ATCC® CCL-185).12 5000 cells/well were seeded in 96-well plates (Greiner Bio-One 
REF#655090) with DMEM (Gibco REF#41965-039) supplemented with 2% FBS (Gibco 
REF#10270-106) and 0.075 g/L sodium bicarbonate (Gibco REF#25080) and incubated 
overnight at 37ºC and 5% CO2. Then a serial dilution of the respective compound was 
added immediately after infected with 500 CCID50 of virus. Both the compound and the virus 
inoculum were kept on the cells during the incubation period of four days. At 4 days post 
infection (dpi) the cells were stained with a 2.5 µg/mL Hoechst (Hoechst 33342, Invitrogen) 
solution. High content imaging (HCI) analysis was performed on the Arrayscan XTI 
(Thermofisher) using a custom analysis protocol based on the SpotDetector 
BioApplication (Cellomics® software). The 50% effective concentration (EC50) is the 
compound concentration that reduces the number of mCherry signal spots by half, compared 
to the virus control. Cell viability was scored based the number of nuclei-containing objects. 
Virus yield assay 
Viral RNA was extracted from cell culture supernatant using the NucleoSpin® kit (Macherey-
Nagel REF#740955) according to the manufacturer’s instructions. Per reaction, a 20 µL RT-
qPCR mix was prepared using the ITaq Universal SYBR Green One-Step kit (Bio-Rad 
CAT#1725151) with 600 nM BUNV-Fw and 900 nM BUNV-Rev primers (Fw: 5’-
ACACCACTGGGCTTAG-3’, Rev: 5’-CAGCCCCCAAGGTTA-3’) on a LightCycler 96 
thermocycler (Roche Diagnostics). For absolute quantification, standard curves were generated 
using 10-fold dilutions of gBlock DNA (IDT) of known concentration. 
Synergy scoring 
Synergy scoring was determined using “inhibition readout” on the online software of 
https://synergyfinder.fimm.fi and implementing the Zero Interaction Potency (ZIP) response 
surface model.13,14 
Results 
We show that BXA contributes to the enzyme’s melting temperature (Tm) in the presence of 
Mn2+, which is in agreement with the chelating nature of the compound. The addition of BXA 
raised the Mn2+ baseline Tm by 9.5 ± 0.4 °C (Δ Tm) (Figure 1A). We additionally 
assessed the impact of BXA on LACV_L1-184_WT catalytic activity via a FRET-based nuclease-
monitoring assay, where BXA inhibited the substrate cleavage in a dose-dependent manner 
with an IC50 value of 0.39 ± 0.03 μM (Figure 1B). 
To further investigate the binding of BXA within the LACV endonuclease, we performed a 
molecular docking simulation. The results show a clear coordination of the chelating motif that 
includes the β-hydroxy ketone and the manganese atoms, with the fluorinated aromatic ring 
establishing a contact with Lys108 and Thr105 (Figure 1C). These results suggest that, despite 
the relatively shallow and extensive nature of the endonuclease catalytic site, BXA is able to 
establish an efficient binding with the enzyme. 
To assess the antiviral activity of BXA and ribavirin against orthobunyaviruses we added a 
serial dilution of the compounds together with BUNV-mCherry onto A549 
cells. At 4 dpi BXA and ribavirin inhibited BUNV-mCherry replication in infected cells with 
an EC50 of 0.7 ± 0.2 µM and 26.6 ± 8.9 µM, respectively (Figure 2A, 2B) as determined 
by HCI analyses. At concentrations of BXA up to 3.13 µM the cell viability remains above 
80%. This is in line with cytotoxicity measured in other studies using MDCK 
cells.7 We confirmed the effect on the inhibition of virus progeny production by virus yield 
assay. The resulting EC50 values are similar to our fluorescence-based readout 
with EC50 of 0.9 ± 0.3 µM and 11.8 ± 1.8 µM for BXA and ribavirin, respectively (Figure 2A, 
2B). 
To determine whether the antiviral effect of ribavirin and BXA could be improved by 
combination, cells were infected with BUNV-mCherry, as in the antiviral activity 
assay, and treated with multiple concentrations of either one or both inhibitors. We identified 
a small concentration range where combination treatment results in a synergistic effect 
of 8.64 as calculated by the ZIP model (Figure 2C). The area with the highest synergistic 
score has an average of 3.53. 
Discussion 
Taken together, this work shows that cap-snatching endonuclease inhibitors like BXA should 
be considered as an option to treat a wide range of orthobunyavirus infections. Learning from 
studies on BXA-treated influenza patients, the highest chance of success will come from 
starting treatment as early as possible.6 Although the use of ribavirin is not recommended due 
to toxicity, the combination with baloxavir would result in a more potent antiviral effect, thus 
lower (non-toxic) doses of ribavirin might suffice. We here demonstrate that targeting 
the endonuclease of orthobunyavirus by the influenza compound BXA yields a more potent 
antiviral effect than ribavirin. Thus, the design of highly potent and selective endonuclease 
inhibitors hold great promise as drug candidates. 
While our results open the door to a possible therapeutic opportunity, further research is needed 
in small animal models. The effect of the prodrug BXM could then be assessed since 
this will have favorable pharmacodynamics. BXM is in the greatest part metabolized via 
UGT1A3, with a minor contribution from CYP3A4. Neither is involved in the metabolism of 
ribavirin, limiting the risk of an undesirable increase in drug exposure.15 Consequently, we urge 
further investigation of the potential benefit of endonuclease targeting compounds in clinical 
settings, particularly in combination therapies. 
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Figure 1. Effect of BXA on the Cap-ENDO of LACV. (A) Thermal stability of LACV_L1-
184_WT in the presence of 10 mM EDTA (black dashed line), 10 mM EDTA plus 25 μM BXA 
(green dashed line), 10 mM MnCl2 (orange solid line) and 10 mM MnCl2 plus 25 μM BXA 
(green solid line). The compound contribution to the stability of the proteins was determined 
by the difference in Tm between the samples containing MnCl2 in the presence and absence of 
BXA (Δ Tm). The lines depict the nonlinear fits of the normalized fluorescence curves to the 
Boltzmann equation. (B) Dose-dependent inhibition of the nuclease activity of LACV_L1-
184_WT by BXA. The reactions were initiated with the addition of 1 μM of FRET-labeled 
ssRNA substrate to the pre-incubated mixtures of 0.25 μM of the enzyme with two-fold serial 
dilutions of BXA. The fluorescent signal arising from the substrate cleavage was measured 
using a Roche LightCycler 480 II at λex / λem = 490 nm / 515 nm. The V0 of the reactions was 
used to calculate the percentage of activity at the different concentrations of the inhibitor. The 
dose-response curves were fit using a four-parameter nonlinear regression. The Δ Tm and the 
IC50 values are the mean and standard deviation from 3 independent experiments. Final 5% 
DMSO concentration was maintained in all assays to favor compound solubility. (C) Proposed 
binding of BXA within the catalytic site of the LACV endonuclease domain. 
Figure 2. BXA in vitro antiviral activity, alone or in combination with ribavirin, against 
orthobunyaviruses. (A) Antiviral effect of BXA on BUNV-mCherry replication at 4 days post 
infection in A549 cells. Viral mCherry signal spots (black bars) and cell viability (solid circles) 
were determined using high-content imaging. Viral RNA yield (white bars) as determined by 
RT-qPCR, n=5. (B) Antiviral effect of ribavirin on BUNV-mCherry replication at 4 dpi 
in A549 cells. Viral mCherry signal spots (black bars) and cell viability (solid circles) were 
determined using high-content imaging. Viral RNA yield (white bars) as determined by RT-
qPCR, n=5. (C) The interaction surface for combinations of BXA and ribavirin. The square 
indicates the most synergistic region. The graphics represent the mean of five independent 
experiments. 
 
